Market Place
Sourcing Support
Kairos Adds City of Hope to Phase 2 ENV105 Trial
03 Dec 2024 //
BUSINESSWIRE
Kairos Pharma Approved to Dual List on Upstream
19 Nov 2024 //
GLOBENEWSWIRE
Kairos Pharma to Present at the LD Micro Main Event XVII
22 Oct 2024 //
GLOBENEWSWIRE
Kairos Pharma To Participate In 2024 Maxim Healthcare Summit
09 Oct 2024 //
GLOBENEWSWIRE
Prevail Partners And InfoWorks Invest In Kairos Pharma Alliance
25 Sep 2024 //
ACCESSWIRE
Kairos Agreement PreCheck Develop Biomarkers for Cancer Resistance
24 Sep 2024 //
GLOBENEWSWIRE
Kairos Pharma Closing of $6.2 Million Initial Public Offering
17 Sep 2024 //
GLOBENEWSWIRE
Kairos goes public with $6M IPO to fund trials of lead cancer drug
17 Sep 2024 //
FIERCE BIOTECH
Kairos Pharma Prices $6.2 Million Initial Public Offering
16 Sep 2024 //
GLOBENEWSWIRE
Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105
30 Jan 2024 //
GLOBENEWSWIRE
Kairos Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105
16 Jan 2024 //
GLOBENEWSWIRE
Kairos gets FDA clearance to begin Phase I trial of glioblastoma therapy
15 Mar 2022 //
CLINICALTRIALSARENA
FDA Approves Kairos` IND Application for Phase 1 Clinical Trial of KROS 201
14 Mar 2022 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.